March 7, 2024 03:41 PM ESTUpdated March 8, 01:07 PM
Pharma
FDA+

BeiGene’s Brukin­sa bags fifth FDA ap­proval, like­ly po­si­tion­ing it for con­tin­ued sales growth

Ayisha Sharma

News Reporter

BeiGene’s Brukin­sa has clinched a fifth US green light in B-cell ma­lig­nan­cies — this time for fol­lic­u­lar lym­phoma (FL) — fur­ther ex­pand­ing its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times